產品屬性：

Cas No.: 347841-46-7

別名: N/A

化學名: N/A

分子式: C24H36D4O4

分子量: 396.6

溶解度: DMF: 10 mg/ml,DMSO: 10 mg/ml,DMSO:PBS(pH 7.2) (1:4): 0.2 mg/ml,Ethanol: 1 mg/ml

儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.

Shipping ConditionEvaluation sample solution : ship with blue ice

All other available size: ship with RT , or blue ice upon request

產品描述：

Ursodeoxycholic acid-d4 (UDCA-d4) is intended for use as an internal standard for the quantification of UDCA by GC- or LC-MS. UDCA is a secondary bile acid formed via epimerization of chenodeoxycholic acid .1,2 UDCA is also a metabolite of lithocholic acid in human liver microsomes.3 It inhibits taurocholic acid uptake in HeLa cells expressing recombinant sodium/taurocholate cotransporting polypeptide (NTCP) with an IC50 value of 3.6 μM.4 UDCA (50 μM) inhibits apoptosis induced by deoxycholic acid or ethanol in primary rat hepatocytes.5 Dietary administration of UDCA blocks DCA-induced increases in the number of TUNEL-positive hepatocytes in rats. Formulations containing UDCA have been used in the treatment of primary biliary cirrhosis.1.Dawson, P.A., and Karpen, S.J.Intestinal transport and metabolism of bile acidsJ. Lipid Res.56(6)1085-1099(2015)

2.Chiang, J.Y.L.Bile acid metabolism and signaling in liver disease and therapyLiver Res.1(1)3-9(2017)

3.Deo, A.K., and Bandiera, S.M.3-Ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of lithocholic acidDrug Metab. Dispos.37(9)1938-1947(2009)

4.Kim, R.B., Leake, B., Cvetkovic, M., et al.Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activityJ. Pharmacol. Exp. Ther.291(3)1204-1209(1999)

5.Rodrigues, C.M.P., Fan, G., Ma, X., et al.A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbationJ. Clin. Invest.101(12)2790-2799(1998)
特別提醒公司產品僅供科研使用